Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials DOI Creative Commons
Syed Nasir Abbas Bukhari

Pharmaceutics, Journal Year: 2022, Volume and Issue: 14(4), P. 866 - 866

Published: April 15, 2022

A key issue with modern cancer treatments is the emergence of resistance to conventional chemotherapy and molecularly targeted medicines. Cancer nanotherapeutics were created in order overcome inherent limitations traditional chemotherapeutics. Over last few decades, provided unparalleled opportunities understand drug through clinical assessment rationally designed nanoparticulate delivery systems. In this context, various design strategies such as passive targeting, active nano-drug, multimodal nano-drug combination therapy effective treatment. Even though nanotherapy has made great technological progress, tumor biology complexity heterogeneity a lack comprehensive knowledge nano-bio interactions remain important roadblocks future translation commercialization. The current developments advancements employing wide variety nanomaterial-based platforms treatment are discussed article. There also review nanotherapeutics-based approaches therapy, including targeting for microenvironment its components, advanced systems specific stem cells (CSC), well exosomes strategies, an update on trials. Finally, challenges perspective reverse discussed.

Language: Английский

Dysregulated Signalling Pathways Driving Anticancer Drug Resistance DOI Open Access

Nauf Bou Antoun,

Athina‐Myrto Chioni

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(15), P. 12222 - 12222

Published: July 30, 2023

One of the leading causes death worldwide, in both men and women, is cancer. Despite significant development therapeutic strategies, inevitable emergence drug resistance limits success impedes curative outcome. Intrinsic acquired are common mechanisms responsible for cancer relapse. Several factors crucially regulate tumourigenesis resistance, including physical barriers, tumour microenvironment (TME), heterogeneity, genetic epigenetic alterations, immune system, burden, growth kinetics undruggable targets. Moreover, transforming factor-beta (TGF-β), Notch, epidermal factor receptor (EGFR), integrin-extracellular matrix (ECM), nuclear kappa-light-chain-enhancer activated B cells (NF-κB), phosphoinositol-3-kinase/protein kinase B/mammalian target rapamycin (PI3K/Akt/mTOR), wingless-related integration site (Wnt/β-catenin), Janus kinase/signal transducers activators transcription (JAK/STAT) RAS/RAF/mitogen-activated protein (MAPK) signalling pathways some key players that have a pivotal role mechanisms. To guide future treatments improve results, deeper comprehension necessary. This review covers intrinsic gives comprehensive overview recent research on enable to bypass barriers put up by treatments, and, like “satellite navigation”, find alternative routes which carry their “journey” progression.

Language: Английский

Citations

48
Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy DOI
Kenneth K.W. To,

Zoufang Huang,

Hang Zhang

et al.

Drug Resistance Updates, Journal Year: 2024, Volume and Issue: 73, P. 101058 - 101058

Published: Jan. 19, 2024

Language: Английский

Citations

20
N6‐methyladenosine reader hnRNPA2B1 recognizes and stabilizes NEAT1 to confer chemoresistance in gastric cancer DOI Creative Commons
Jiayao Wang, Jiehao Zhang, Hao Liu

et al.

Cancer Communications, Journal Year: 2024, Volume and Issue: 44(4), P. 469 - 490

Published: March 21, 2024

Abstract Background Chemoresistance is a major cause of treatment failure in gastric cancer (GC). Heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) an N6‐methyladenosine (m 6 A)‐binding protein involved variety cancers. However, whether m A modification and hnRNPA2B1 play role GC chemoresistance largely unknown. In this study, we aimed to investigate the downstream mechanism chemoresistance. Methods The expression among public datasets were analyzed validated by quantitative PCR (qPCR), Western blotting, immunofluorescence, immunohistochemical staining. biological functions investigated both vitro vivo. RNA sequencing, methylated immunoprecipitation, stability assay performed assess association between binding RNA. maintenance stemness was evaluated bioinformatic analysis, qPCR, sphere formation assays. patterns regulators specimens from patients who received adjuvant chemotherapy RNAscope multiplex immunohistochemistry. Results Elevated found cells tissues, especially multidrug‐resistant (MDR) cell lines. associated with poor outcomes patients, those 5‐fluorouracil treatment. Silencing effectively sensitized inhibiting proliferation inducing apoptosis Mechanically, interacted stabilized long noncoding NEAT1 A‐dependent manner. Furthermore, worked together enhance properties via Wnt/β‐catenin signaling pathway. clinical subjected chemotherapy, levels hnRNPA2B1, NEAT1, CD133, CD44 markedly elevated non‐responders compared responders. Conclusion Our findings indicated that interacts stabilizes lncRNA which contribute property pathway exacerbate GC.

Language: Английский

Citations

20
Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review DOI Open Access
Nilesh Kumar Sharma, Anjali Bahot,

Gopinath Sekar

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(4), P. 680 - 680

Published: Feb. 6, 2024

In recent years, the emergence of cancer drug resistance has been one crucial tumor hallmarks that are supported by level genetic heterogeneity and complexities at cellular levels. Oxidative stress, immune evasion, metabolic reprogramming, overexpression ABC transporters, stemness among several key contributing molecular response mechanisms. Topo-active drugs, e.g., doxorubicin topotecan, clinically active utilized extensively against a wide variety human tumors often result in development failure to therapy. Thus, there is an urgent need for incremental comprehensive understanding mechanisms specifically context topo-active drugs. This review delves into intricate mechanistic aspects these intracellular extracellular explores use potential combinatorial approaches utilizing various drugs inhibitors pathways involved resistance. We believe this will help guide basic scientists, pre-clinicians, clinicians, policymakers toward holistic interdisciplinary strategies transcend resistance, renewing optimism ongoing battle cancer.

Language: Английский

Citations

17
Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs DOI

Wenxiao Jiang,

Jun Xia, Shangdan Xie

et al.

Drug Resistance Updates, Journal Year: 2020, Volume and Issue: 50, P. 100683 - 100683

Published: Feb. 25, 2020

Language: Английский

Citations

115
Current scenario of indole derivatives with potential anti-drug-resistant cancer activity DOI
Yanshu Jia,

Xiaoyue Wen,

Yufeng Gong

et al.

European Journal of Medicinal Chemistry, Journal Year: 2020, Volume and Issue: 200, P. 112359 - 112359

Published: April 27, 2020

Language: Английский

Citations

100
The role of non‐coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential DOI Creative Commons
Xiang Meng,

Qiuyue Lou,

Wenying Yang

et al.

Cancer Communications, Journal Year: 2021, Volume and Issue: 41(10), P. 981 - 1006

Published: July 20, 2021

Oral squamous cell carcinoma (OSCC), the eighth most prevalent cancer in world, arises from interaction of multiple factors including tobacco, alcohol consumption, and betel quid. Chemotherapeutic agents such as cisplatin, 5-fluorouracil, paclitaxel have now become first-line options for OSCC patients. Nevertheless, patients eventually acquire drug resistance, leading to poor prognosis. With discovery identification non-coding RNAs (ncRNAs), functions dysregulated ncRNAs development resistance are gradually being widely recognized. The mechanisms intricate involve efflux, epithelial-mesenchymal transition, DNA damage repair, autophagy. At present, strategies explore reversal need be urgently developed. Nano-delivery self-cellular delivery platforms considered effective overcome due their tumor targeting, controlled release, consistent pharmacokinetic profiles. In particular, combined application new technologies (including CRISPR systems) opened up horizons treatment OSCC. Hence, this review explored emerging regulatory OSCC, elucidated ncRNA-meditated discussed potential value using nanoparticles self-cells carriers

Language: Английский

Citations

92
The state of CD44 activation in cancer progression and therapeutic targeting DOI Open Access
Qian Guo,

Cuixia Yang,

Feng Gao

et al.

FEBS Journal, Journal Year: 2021, Volume and Issue: 289(24), P. 7970 - 7986

Published: Sept. 3, 2021

CD44, a non-kinase transmembrane glycoprotein, is ubiquitously expressed on various types of cells, especially cancer stem cells (CSCs), and has been implicated in onset aggressiveness. The major ligand for the hyaluronan (HA), binds to interacts with which turn triggers downstream signaling cascades, thereby promoting cellular behaviors such as proliferation, motility, invasiveness chemoresistance. CD44-HA interaction cell-specific strongly affected by state CD44 activation. Therefore, binding HA essential activation during detailed regulatory mechanism needs be clarified. Different states distribute human carcinoma normal tissue; however, whether critical requirement tumor initiation, progression notorious CSC properties remains A deeper understanding regulation may facilitate development novel targeted drugs future. Here, we review current findings concerning cell surface, underlying mechanisms activation, known role hallmarks, well potential HA-coated nanoparticle targeting activated therapy.

Language: Английский

Citations

91
Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy DOI Creative Commons
Raefa Abou Khouzam, Goutham Hassan Venkatesh, Rania F. Zaarour

et al.

Seminars in Cancer Biology, Journal Year: 2020, Volume and Issue: 65, P. 140 - 154

Published: Jan. 9, 2020

Language: Английский

Citations

84
The Molecular Basis and Therapeutic Aspects of Cisplatin Resistance in Oral Squamous Cell Carcinoma DOI Creative Commons
Yali Cheng, Shaoming Li, Ling Gao

et al.

Frontiers in Oncology, Journal Year: 2021, Volume and Issue: 11

Published: Oct. 22, 2021

Oral squamous cell carcinoma (OSCC) is a kind of malignant tumors with low survival rate and prone to have early metastasis recurrence. Cisplatin an alkylating agent which induces DNA damage through the formation cisplatin-DNA adducts, leading cycle arrest apoptosis. In management advanced OSCC, cisplatin-based chemotherapy or chemoradiotherapy has been considered as first-line treatment. Unfortunately, only portion OSCC patients can benefit from cisplatin treatment, both inherent resistance acquired greatly limit efficacy even cause treatment failure. Herein, this review outline underlying mechanisms in aspects repair, epigenetic regulation, transport processes, programmed death tumor microenvironment. addition, summarizes strategies applicable overcome resistance, provide new ideas improve clinical therapeutic outcome OSCC.

Language: Английский

Citations

81